In its second big pharma deal, Epizyme has formed a global partnership with Eisai to discover, develop and commercialise small molecules targeting EZH2, an epigenetic enzyme, for the potential treatment of lymphoma and other cancers in genetically defined patients. The deal provides Epizyme, a key player in the emerging field of epigenetics, with the right to opt into a profit share and co-commercialisation relationship for the US.